publication date: January 10, 2025
|
writer/source: AMS Biotechnology (Europe) Ltd
Membrane proteins constitute over 60% of all FDA-approved drug targets and 90% of antibody drug targets. Many traditional sample preparation methods face challenges in obtaining water-soluble and bioactive forms of multipass transmembrane proteins.
Commonly, detergent is widely used to supply multipass transmembrane proteins. However, the fundamental drawback of this system is that the detergent can’t be completely removed. This could also be problematic in downstream applications since the presence of detergent may interfere with experiments or affect the structure of the protein.
An alternative technique for obtaining proteins with good solubility and proper folding is the use of peptides derived from the N-terminus or extracellular loops. Unfortunately, transmembrane proteins prepared by this method may not retain the structural features and conformation of the unique extracellular loops of the transmembrane protein in the native membrane.
Another method is to make use of membrane fractions, whole cells, or VLPs to keep up the native structure of transmembrane proteins, but immunization with these products has been shown to result in high levels of nonspecific background antibodies.
Based on an progressive polymer-based platform, synthetic nanodiscs offer a more advanced solution in comparison with traditional solutions. Synthetic nanodiscs have been shown to supply full-length membrane proteins with high purity and excellent solubility in aqueous solutions in many applications. Advantageously, the proteins contained in synthetic nanodiscs are situated in the native membrane environment, which ensures their biological activity. These products don’t contain detergent, making them suitable to be used in cell tests and other experiments. Overall, synthetic nanodiscs eliminate the necessity for membrane scaffold proteins, creating an improved cleansing system with reduced interference with downstream testing. In this manner, our synthetic nanodiscs enable the functional characterization of multipass transmembrane proteins in their active form, revolutionizing membrane protein research and drug development.
About AMS Biotechnology
Founded in 1987, AMS Biotechnology (AMSBIO) is today recognized as a number one transatlantic company helping to speed up discovery by providing cutting-edge life science technologies, services for research and development in the fields of medicine, nutrition, cosmetics and energy. industries. AMSBIO has in-depth knowledge of extracellular matrices to supply elegant solutions for studying cell motility, migration, invasion and proliferation. This expertise in cell culture and ECM enables AMSBIO to work with customers to customize cell systems to enhance organoid and spheroid screening results using a range of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers tests, recombinant proteins and cell lines. Based on a big and comprehensive biorepository, AMSBIO is well known as a number one supplier of high-quality tissue samples (including custom samples) from each human and animal tissues. The company provides unique clinical-grade products for stem cell and cell therapy applications. This includes GMP cryopreservation technology and high-quality virus delivery solutions.
The latest news from AMSBIO
